J. Brantley Thrasher

AUA president: In uncertain times, urologists must unify
AUA president: In uncertain times, urologists must unifyIn this interview, newly elected AUA President J. Brantley Thrasher, MD, discusses the organization’s expanded efforts in advocacy, research, and education.
When is a patient cured after prostatectomy?"Rather than making a blanket statement regarding continued follow-up, we need to consider the pathologic features commonly known to increase the risk of [prostate cancer] recurrence—concurrent medical problems, the patient’s age at recurrence, PSA doubling time, longevity in the family, etc," writes J. Brantley Thrasher, MD.
Committee seeks to ban concurrent surgeriesThe practice of performing concurrent and overlapping surgeries in hospitals and ambulatory surgery centers across the nation has come under scrutiny by the Senate Finance Committee, and hospitals and surgeons are on notice that some practices that may have been commonplace in the past need to change.
MOC: Members of the UT editorial board weigh inIn conjunction with Urology Times' recent coverage of maintenance of certification (MOC), we asked several members of the UT Editorial Advisory Board to weigh in with their thoughts on MOC.
Is mpMRI ready for prostate Ca screening?"Avoiding unnecessary biopsies should be a high-priority goal for us all," writes J. Brantley Thrasher, MD.
CRPC document aids in complex decisionsIn its current iteration, the AUA's CRPC guideline contains 20 statements relating to treatments for six index patients defined by the presence or absence of metastatic disease, presence and degree of symptoms, ECOG performance status, and prior treatment with docetaxel (Taxotere) along with two statements on the use of preventive treatments for bone health.
AUA 2016: Experts offer guidance on the meetingTo guide you through the 2016 AUA annual meeting and help maximize your time, Urology Times’ editorial board has reviewed the program to identify the key trends and noteworthy research at this year’s meeting.
Markers redefining prostate cancer careIn this interview, Daniel W. Lin, MD, discusses the practical use of currently available molecular and genomic tests, cost and reimbursement considerations, the role of MRI, and what the future holds for biomarkers.
PCa agent detects 97% of lesions when paired with PETThe investigational modality was compared with surgical pathology in men undergoing radical prostatectomy.
Renal biopsy may alter management in high-risk patientsIn this interview, E. Jason Abel, MD, discusses biopsy’s role in small and large renal masses, associated risks, and when patients can be safely observed.